Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable Quarter ...

Negative Points

• Medicare and Medicare Advantage represent ~45% of payer mix, and the current bundled payment structure covers only up to four tests per patient lifetime, creating ASP pressure as testing frequency increases.

• US ASP was $1,380 in Q3, relatively flat sequentially, and reaching the full-year target of ~$1,400 depends on timing of coverage expansions and frequency uptake.

• The company does not anticipate GAAP net income or positive EPS for Q4 or the full year, despite Q3 GAAP net income of $2.8 million.

• Pharma revenue can be lumpy quarter-to-quarter, and the timing of milestone payments is difficult to predict, with no milestones assumed for the remainder of the year.

• CMS published preliminary 2027 rates with erroneous data on the ClonoSeq PLA code, creating near-term uncertainty, though the company is working to correct it before final rates.

Q & A Highlights

Q: How exposed is ClonoSeq to the CMS draft rates for 2027, and what levers can offset ASP pressure? A: CFO Kyle Piskel said Adaptive is not an applicable laboratory under PAMA and did not submit private payer data to CMS. The company identified erroneous data submitted on the ClonoSeq PLA code and is working with CMS to correct it before rates are finalized in November. Because most Medicare revenue flows through the episodic bundled structure, the company does not believe PLA rate-setting should affect that framework, and it remains confident in its long-term pricing strategy.

Q: What will be the biggest growth lever for ClonoSeq in 2027? A: CEO Chad Robins, while not guiding on 2027, said he sees no reason growth won't remain high, citing favorable NCCN guidelines and the new cure definition as foundations. Key enablers are EMR integration (with a focus on optimizing serial testing pull-through, such as 78% fulfillment in Flatiron accounts), blood-based testing (up 68% year over year, 51% of volume), and community expansion (37% of volume).

Q: What is driving the strong sequential growth in DLBCL, and is it sustainable given competitive noise? A: Robins said DLBCL growth is broad-based across community and academic accounts, with the largest gains coming from one of the country's biggest community networks. He cited ClonoSeq's lymphoma-specific design, broad reimbursement, real-world experience with about 9,000 patients tested, and strong customer relationships as moats. He expects consistent double-digit growth and views competitor noise as disproportionately beneficial to the market leader in an underpenetrated market.

Q: What is driving the surge in multiple myeloma pharma bookings and backlog? A: Robins attributed it to three factors: FDA draft guidance cementing MRD as an accelerated endpoint, which spurred new primary-endpoint studies; the new IMS cure definition prompting more testing time points to support cure claims and higher bookings per study; and growing interventional use, with 23 interventional studies now including eight in myeloma. Myeloma represents about 60% of active studies and 65% of backlog.

Q: How should investors think about the path to the $1,400 ASP target and the longer-term $1,700-$1,800 goal? A: Piskel said blocking and tackling contributes each quarter, but Medicare testing frequency creates some timing variability. Robins noted that ASP pressure from patients exceeding the four-test Medicare bundle is actually the evidence supporting the Moldex submission for an additional five-test maintenance bundle, with recurrence monitoring data expected in myeloma in the second half of the year. He said discussions are positive and he is more confident than ever in hitting, and potentially accelerating, the $1,700-$1,800 target.

Q: What is baked into Q4 pharma guidance, and what milestone opportunities lie ahead? A: Piskel said pharma revenue can be lumpy quarter to quarter, but backlog of $270 million (up from $200 million a year ago) supports roughly 25% full-year sequencing growth excluding milestones. No Q4 milestones are assumed in guidance; the company will update when it has line of sight, noting timing is difficult to predict but a healthy backlog of milestone opportunities remains over the coming years.

Q: With company-wide profitability achieved, how is Adaptive thinking about capital deployment and potential tuck-in acquisitions? A: Robins said the best use of profits is reinvesting to expand moats and accelerate MRD adoption. 2026 investments focused on real-world data, AI-driven automation of revenue cycle management, and next-generation customer experience to facilitate serial testing, with continued investment planned in 2027. He also highlighted R&D for product enhancements, new applications of the immunosequencing platform beyond hematology, and openness to disciplined tuck-ins.

Q: How meaningful is the NCCN guideline recognition for a market leader like ClonoSeq? A: Robins said the benefit is most substantial in community oncology, where clinicians rely on guidelines for how and when to test. Adaptive is promoting the updates and helping practices standardize testing pathways, which ties into its EMR integration strategy. He called it a potentially meaningful accelerator for the myeloma business and a support for the Moldex maintenance bundle submission, and noted the guidelines plus cure definition underscore bone marrow testing as a complement to blood.

Q: How should investors frame clinical volume growth as the company laps strong 2026 comparisons into 2027? A: Robins declined to guide on 2027 but said there is tremendous internal excitement, with the new cure definition and updated NCCN guidelines providing strong call points, particularly in the community. He said the company sees nothing slowing momentum and expects the trajectory to continue, supported by the two major industry updates.

Q: What were the key Q3 financial results and the updated 2026 guidance? A: Piskel reported total revenue of $83.9 million, up 39% year over year, with MRD revenue of $72.6 million (up 44% excluding prior-year milestones) and immune medicine revenue of $11.3 million from the Pfizer agreement. Total company adjusted EBITDA was positive at $14.3 million and GAAP net income was $2.8 million, though GAAP profitability is not expected in Q4 or the full year. Full-year MRD revenue guidance was raised to $276 million-$286 million, implying about 41% growth excluding milestones, with opex of approximately $350 million.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .